Molecular Forecaster and TransBIOTech join forces to accelerate the discovery of new small molecule therapeutics
MONTREAL AND LÉVIS, CANADA, JUNE 16, 2025 - Molecular Forecaster Inc.(MFI) and TransBIOTech are pleased to announce a strategic partnership that leverages the complementary strengths of both organizations to develop drug discovery programs combining MFI's customized computer-aided design (CADD) solutions with TransBIOTech's in vitro and in vivo expertise.
MFI and TransBIOTech share the mission of accelerating the design and preclinical development of drugs. MFI is a research-as-a-service(RaaS) organization that combines human expertise and proprietary technology to integrate chemistry and computational modeling, reducing design cycles in small molecule campaigns. TransBIOTech is a college research center affiliated with Cégep de Lévis. The organization offers cutting-edge expertise in cellular and molecular biology, pharmacology and analytical chemistry to accelerate the steps towards clinical trials of new therapeutic molecule candidates through customized preclinical efficacy and safety studies.
This partnership strengthens the synergies between computational and preclinical research, facilitating the transition from in silico prediction to in vitro and in vivo validation. Thanks to this collaboration, TransBIOTech is now able to offer integrated computer-aided design solutions combining MFI's in silico predictions with customized experimental validation. MFI's customers and partners will benefit from direct access to preclinical research laboratories and expertise in candidate optimization, enabling rapid validation and risk reduction before the GLP (Good Laboratory Practice) certification stage.
"It's crucial right now to strengthen the life sciences ecosystems in Quebec, Canada, and other jurisdictions around the world," says Joshua Pottel, founder and CEO of Molecular Forecaster. "At MFI, we choose to collaborate with organizations that create opportunities for our customers and the marketplace. Our relationship with TransBIOTech builds a strong bridge between computational and experimental expertise, enabling our customers to link computational modeling results to concrete experimental data quickly and efficiently."
"By partnering with Molecular Forecaster, we are strengthening our support for companies developing new drug candidates," adds Delphine Davan, Head of Partnerships and Business Development at TransBIOTech. "This strategic collaboration will enable us to offer a complete and integrated chain of expertise, from molecular modeling to preclinical validation."
– 30 –
About Molecular Forecaster Inc.
Molecular Forecaster Inc (MFI) helps companies make smarter drug design decisions. For the past six years, we've been democratizing computer-aided drug design through our highly collaborative Research-as-a-Service model. Today, we're integrating what we've learned into new and improved software tools. Our goal? To become the go-to partner for small molecule drug design, by combining proprietary tools and technologies, our expertise and know-how, and our holistic approach to collaboration that sets our partners up for success.
Contact: Josh Pottel, CEO
About TransBIOTech
TransBIOTech, a Centre collégial de transfert de technologie (CCTT) affiliated with Cégep de Lévis, QC, Canada, is a research center and non-profit organization specializing in biotechnology. Since 1999, TransBIOTech has provided expert support in drug development, offering customized services in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics and toxicology. TransBIOTech researchers use their expertise and advanced methodologies to evaluate the mechanism of action, efficacy and safety of therapeutic molecules at different stages of preclinical development.
Contact: Delphine Davan, Director of Partnerships and Business Development
